These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7287 related articles for article (PubMed ID: 22489330)

  • 1. Targeting leucine addiction and autophagy in melanoma.
    Diaz-Meco MT
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):588-9. PubMed ID: 22489330
    [No Abstract]   [Full Text] [Related]  

  • 2. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo.
    Sheen JH; Zoncu R; Kim D; Sabatini DM
    Cancer Cell; 2011 May; 19(5):613-28. PubMed ID: 21575862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
    J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway.
    Yang Y; Ma S; Ye Z; Zhou X
    J Cell Biochem; 2020 Feb; 121(2):1283-1294. PubMed ID: 31535400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPK and autophagy get connected.
    Hardie DG
    EMBO J; 2011 Feb; 30(4):634-5. PubMed ID: 21326174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glutamine transport to suppress melanoma cell growth.
    Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
    Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcl-1 is required for melanoma cell resistance to anoikis.
    Boisvert-Adamo K; Longmate W; Abel EV; Aplin AE
    Mol Cancer Res; 2009 Apr; 7(4):549-56. PubMed ID: 19372583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.
    Kardos GR; Wastyk HC; Robertson GP
    Mol Cancer Res; 2015 Oct; 13(10):1408-20. PubMed ID: 26082174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF.
    Maddodi N; Huang W; Havighurst T; Kim K; Longley BJ; Setaluri V
    J Invest Dermatol; 2010 Jun; 130(6):1657-67. PubMed ID: 20182446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
    Werzowa J; Koehrer S; Strommer S; Cejka D; Fuereder T; Zebedin E; Wacheck V
    J Invest Dermatol; 2011 Feb; 131(2):495-503. PubMed ID: 21048785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
    Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
    Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX4 Promotes Proliferative Signals by Regulating Glycolysis through AKT Activation in Melanoma Cells.
    Dai W; Xu X; Li S; Ma J; Shi Q; Guo S; Liu L; Guo W; Xu P; He Y; Zhu G; Wang L; Ge R; Liu Y; Jian Z; Wang G; Shen L; Gao T; Li C
    J Invest Dermatol; 2017 Nov; 137(11):2407-2416. PubMed ID: 28760661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
    Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue.
    Rouaud F; Boucher JL; Slama-Schwok A; Rocchi S
    Oncotarget; 2016 Dec; 7(50):82804-82819. PubMed ID: 27756874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mutant NRAS signaling pathways in melanoma.
    Vu HL; Aplin AE
    Pharmacol Res; 2016 May; 107():111-116. PubMed ID: 26987942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the pro-survival molecule Bfl-1 in melanoma.
    Hind CK; Carter MJ; Harris CL; Chan HT; James S; Cragg MS
    Int J Biochem Cell Biol; 2015 Feb; 59():94-102. PubMed ID: 25486183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 365.